agree they dont want to undertake m&a just because of fcf
they have large debt from teva acquisition so need to pau that down first
look at companies like teva on nyse recently that have lost almost 50% off sp to know that acquisitions funded by massive debt can hurt eps and patent issues on ip protected products are toxic
therefore myxneeds to consolidate for a period and concentrate on new product marketing plus their manufacturing capex to grow future eps.
MYX Price at posting:
$1.31 Sentiment: Buy Disclosure: Held
